Search Results - "Ye, Darwin Q."

Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent by Xiang, Michael, Kim, Haesook, Ho, Vincent T., Walker, Sarah R., Bar-Natan, Michal, Anahtar, Melodi, Liu, Suhu, Toniolo, Patricia A., Kroll, Yasmin, Jones, Nichole, Giaccone, Zachary T., Heppler, Lisa N., Ye, Darwin Q., Marineau, Jason J., Shaw, Daniel, Bradner, James E., Blonquist, Traci, Neuberg, Donna, Hetz, Claudio, Stone, Richard M., Soiffer, Robert J., Frank, David A.

“…The oncogenic transcription factor signal transducer and activator of transcription 3 (STAT3) is frequently activated inappropriately in a wide range of…”
Get full text

Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer by Liu, Suhu, Gandler, Helen I, Tošić, Isidora, Ye, Darwin Q, Giaccone, Zachary T, Frank, David A

“…Pancreatic cancer is characterized by aberrant activity of oncogenic KRAS, which is mutated in 90% of pancreatic adenocarcinomas. Because KRAS itself is a…”
Get full text

Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia by Toniolo, Patricia A, Liu, Suhu, Yeh, Jennifer E, Ye, Darwin Q, Barbuto, José Alexandre M, Frank, David A

“…One cause of morbidity and mortality in chronic lymphocytic leukemia (CLL) is infection, which results from defects in a number of components of the immune…”
Get full text

The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy by Liu, Suhu, Marneth, Anna E., Alexe, Gabriela, Walker, Sarah R., Gandler, Helen I., Ye, Darwin Q., Labella, Katherine, Mathur, Radhika, Toniolo, Patricia A., Tillgren, Michelle, Gokhale, Prafulla C., Barbie, David, Mullally, Ann, Stegmaier, Kimberly, Frank, David A.

“…To identify novel therapeutic targets in acute myeloid leukemia (AML), we examined kinase expression patterns in primary AML samples. We found that the…”
Get full text

Abstract B32: Mutant KRAS downregulates LIFR to enhance glycolysis in pancreatic cancer by Liu, Suhu, Gandler, Helen I., Walker, Sarah R., Ye, Darwin Q., Giaccone, Zachary T., Nowak, Jonathan A., Aguirre, Andrew J., Wolpin, Brian M., Frank, David A.

“…Abstract One of the hallmarks of pancreatic cancer is aberrant activity of oncogenic KRAS, which is mutated and constitutively activated in greater than 90% of…”
Get full text